DIFFERENTIAL EXPRESSION OF FGFRs SIGNALING
PATHWAY COMPONENTS IN BLADDER CANCER:
A STEP TOWARD PERSONALIZED MEDICINE Ousati Ashtiani Z1,2, Tavakkoly-Bazzaz J2,*, Salami SA3,
Pourmand MR4, Mansouri F5,6, Mashahdi R1, Pourmand G1,* *Corresponding Author: Professor Gholamreza Pourmand, Urology Research Center, Sina Hospital, Tehran University Medical Sciences,
Hasan Abad Square, Tehran, 113746911, Iran. Tel: +98-216-634-8560. Fax: +98-216-634-8561. Email: pourmand@tums.ac.ir and/
or Associate Professor Javad Tavakkoly-Bazzaz, Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences,
Poursina Street, Tehran, 1417613151, Iran. Tel: +98-218-895-3005. Fax: +98-218-895-3005. Email: tavakkolybazzazj@tums.ac.ir page: 75
|
REFERENCES
1. Rodriguez-Vida A, Saggese M, Hughes S, Rudman S,
Chowdhury S, Smith NR, et al. Complexity of FGFR
signalling in metastatic urothelial cancer. J Hematol
Oncol. 2015; 8: 119. doi: 10.1186/s13045-015-0221-6.
2. Knowles MA, Hurst CD. Molecular biology of bladder
cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 2015; 15(1): 25-41.
3. Li H-T, Duymich CE, Weisenberger DJ, Liang G.
Genetic and epigenetic alterations in bladder cancer.
Inter Neurourol J. 2016; 20(Suppl 2): S84-S94.
4. Nagata M, Muto S, Horie S. Molecular biomarkers
in bladder cancer: Novel potential indicators of prognosis
and treatment outcomes. Dis Markers. 2016;
2016: 8205836. doi: 10.1155/2016/8205836.
5. Martin GS. Cell signaling and cancer. Cancer Cell.
2003; 4(3): 167-174.
6. Ornitz DM, Itoh N. The fibroblast growth factor signaling
pathway. WIREs Dev Biol. 2015; 4(3): 215-266.
7. Wesche J, Haglund K, Haugsten EM. Fibroblast
growth factors and their receptors in cancer. Biochem
J. 2011; 437(2): 199-213.
8. di Martino E, Tomlinson DC, Knowles MA. A decade
of FGF receptor research in bladder cancer: Past,
present, and future challenges. Adv Urol. 2012; 2012:
429213. doi: 10.1155/2012/429213.
9. Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho
do Y, et al. Fibroblast growth factor receptor 1 overexpression
is associated with poor survival in patients
with resected muscle invasive urothelial carcinoma.
Yonsei Med J. 2016; 57(4): 831-839.
10. Dienstmann R, Rodon J, Prat A, Perez-Garcia J,
Adamo B, Felip E, et al. Genomic aberrations in the
FGFR pathway: Opportunities for targeted therapies
in solid tumors. Ann Oncol. 2014; 25(3): 552-563.
11. Wang Z, Zhang C, Sun L, Liang J, Liu X, Li G, et
al. FGFR3, as a receptor tyrosine kinase, is associated
with differentiated biological functions and
improved survival of glioma patients. Oncotarget.
2016; 7(51):98587-84593.
12. Yashiro M, Matsuoka T. Fibroblast growth factor receptor
signaling as therapeutic targets in gastric cancer.
World J Gastroenterol. 2016; 22(8): 2415-2423.
13. Theelen WS, Mittempergher L, Willems SM, Bosma
AJ, Peters DD, van der Noort V, et al. FGFR1, 2 and
3 protein overexpression and molecular aberrations
of FGFR3 in early stage non-small cell lung cancer.
J Pathol Clin Res. 2016; 2(4): 223-233.
14. Yan J, Jingbo C, Wang D, Xie S, Yuan L, Zhong X,
et al. A correlation between decreased parathyroid
alpha-Klotho and fibroblast growth factor receptor
1 expression with pathological category and parathyroid
gland volume in dialysis patients. Inter Urol
Nephrol. 2015; 47(4): 701-706.
15. Serizawa RR, Ralfkiær U, Steven K, Lam GW, Schmiedel
S, Schüz J, et al. Integrated genetic and epigenetic
analysis of bladder cancer reveals an additive diagnostic
value of FGFR3 mutations and hypermethylation
events. Inter J Cancer. 2011; 129(1): 78-87.
16. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW,
van der Kwast TH, Zwarthoff EC. FGFR3, HRAS,
KRAS, NRAS and PIK3CA mutations in bladder cancer
and their potential as biomarkers for surveillance
and therapy. PLoS One. 2010; 5(11): e13821.
17. Juanpere N, Agell L, Lorenzo M, De Muga S, López-
Vilaró L, Murillo R, et al. Mutations in FGFR3 and
PIK3CA, singly or combined with RAS and AKT1,
are associated with AKT but not with MAPK pathway
activation in urothelial bladder cancer. Hum Pathol.
2012; 43(10): 1573-1582. 18. Abdul-Maksoud RS, Shalaby SM, Elsayed WS,
Elkady S. Fibroblast growth factor receptor 1 and
cytokeratin 20 expressions and their relation to prognostic
variables in bladder cancer. Gene. 2016; 591(2):
320-326.
19. Sung JY, Sun JM, Chang Jeong B, Il Seo S, Soo Jeon
S, Moo Lee H, et al. FGFR3 overexpression is prognostic
of adverse outcome for muscle-invasive bladder
carcinoma treated with adjuvant chemotherapy.
Urol Oncol. 2014; 32(1): 49.e23-e31.
20. Guancial EA, Werner L, Bellmunt J, Bamias A,
Choueiri TK, Ross R, et al. FGFR3 expression in
primary and metastatic urothelial carcinoma of the
bladder. Cancer Med. 2014; 3(4): 835-844.
21. Bertz S, Abee C, Schwarz-Furlan S, Alfer J, Hofstadter
F, Stoehr R, et al. Increased angiogenesis
and FGFR protein expression indicate a favourable
prognosis in bladder cancer. Virchows Archiv. 2014;
465(6): 687-695.
22. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-
mediated carcinogenesis. Biochim Biophys Acta.
2012; 1823(4): 850-860.
23. Netto GJ. Molecular biomarkers in urothelial carcinoma
of the bladder: are we there yet? Nat Rev Urol.
2011; 9(1): 41-51.
24. Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom
R, Heidenreich A, et al. Fibroblast growth factor receptor
(FGFR) gene amplifications are rare events in
bladder cancer. Histopathol. 2015; 66(5): 639-649.
25. Lamont FR, Tomlinson DC, Cooper PA, Shnyder
SD, Chester JD, Knowles MA. Small molecule FGF
receptor inhibitors block FGFR-dependent urothelial
carcinoma growth in vitro and in vivo. Brit J Cancer.
2011; 104(1): 75-82.
26. Maeng YH, Eun SY, Huh JS. Expression of fibroblast
growth factor receptor 3 in the recurrence of nonmuscle-
invasive urothelial carcinoma of the bladder.
Korean J Urol. 2010; 51(2): 94-100.
27. Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM.
Expression of fibroblast growth factor receptor family
members is associated with prognosis in early stage
cervical cancer patients. J Transl Med. 2016; 14(1): 124.
28. Zhou W, Du X, Song F, Zheng H, Chen K, Zhang W,
et al. Prognostic roles for fibroblast growth factor receptor
family members in malignant peripheral nerve
sheath tumor. Oncotarget. 2016; 7(16): 22234-22244.
29. Cheng T, Roth B, Choi W, Black PC, Dinney C,
McConkey DJ. Fibroblast growth factor receptors-1
and -3 play distinct roles in the regulation of bladder
cancer growth and metastasis: Implications for
therapeutic targeting. PLoS One. 2013; 8(2): e57284.
30. Chen Y, Xie X, Li X, Wang P, Jing Q, Yue J, et al.
FGFR antagonist induces protective autophagy in
FGFR1-amplified breast cancer cell. Biochem Biophys
Res Commun. 2016; 474(1): 1-7.
31. Tomlinson DC, Knowles MA. Altered splicing of
FGFR1 is associated with high tumor grade and stage
and leads to increased sensitivity to FGF1 in bladder
cancer. Am J Pathol. 2010; 177(5): 2379-2386.
32. Gibney ER, Nolan CM. Epigenetics and gene expression.
Heredity (Edinb). 2010; 105(1): 4-13.
|
|
|
|
|
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|